Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 22;10(2):2045894020907881.
doi: 10.1177/2045894020907881. eCollection 2020 Apr-Jun.

Implantable system for treprostinil: a real-world patient experience study

Shelley Shapiro  1 , Robert C Bourge  2 , Patti Pozella  3 , David F Harris  4 , Erick H Borg  3 , Andrew C Nelsen  3
Affiliations

Implantable system for treprostinil: a real-world patient experience study

Shelley Shapiro et al. Pulm Circ. .

Abstract

Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via an external pump places a significant burden on patients. Consequently, the Implantable System for Remodulin© (treprostinil) was developed and is associated with a low rate of complications (United Therapeutics (Research Triangle Park, NC) in collaboration with Medtronic, Inc. (Mounds View, MN)). The current real-world experience study evaluated pulmonary arterial hypertension patients' perceptions of their quality of life, ability to perform activities of daily living, perceptions on the benefits and risks of the implantable system, and their social interactions before and after receiving the implantable system. Pulmonary arterial hypertension patients who had been transitioned from an external infusion pump to the implantable system completed a mix of quantitative and qualitative questions administered online over the course of a six-day period. A total of 20 patients completed the study. All patients reported that their quality of life, confidence out in public, and ability to travel long distances had improved. Over 90% of patients reported that their overall level of independence was better since receiving the implantable system, and most patients indicated that their ability to independently perform specific activities of daily living had improved. Responses to the qualitative questions suggested that the implantable system saved time, improved interpersonal relationships, and increased freedom. Results from this real-world patient experience study suggest this novel delivery system provides improvements in factors that are of substantial importance to patients.

Keywords: physical activity; prostacyclin; pulmonary arterial hypertension; quality of life; treprostinil.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Overview of the Implantable System for Remodulin.
Fig. 2.
Fig. 2.
Impact of the implantable system on quality of life and activities of daily living—previous IV patients (N = 14).
Fig. 3.
Fig. 3.
Impact of the implantable system on quality of life and activities of daily living—previous SC patients (N = 12).
Fig. 4.
Fig. 4.
Example of letter to someone considering the implantable system.
See this image and copyright information in PMC

References

    1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia (English ed) 2016; 69: 177. - PubMed
    1. Klinger JR, Elliott G, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults 2018: update of the CHEST guideline and expert panel report. Chest 2019; 155: 565–586. - PubMed
    1. Skoro-Sajer N, Gerges C, Balint OH, et al. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart (British Cardiac Society) 2018; 104: 1195–1199. - PMC - PubMed
    1. Grunig E, Benjamin N, Lange TJ, et al. Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial. Respiration 2016; 92: 362–370. - PubMed
    1. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804. - PubMed